江苏康为世纪生物科技股份有限公司 关于首次公开发行前股票期权行权限售股上市流通的公告

Core Points - The company will have 434,236 shares listed for circulation on December 22, 2025, as part of its stock option incentive plan [1][2][4] - The total number of shares after the initial public offering (IPO) was 93,161,111, which has since increased to 112,493,716 shares due to stock option exercises and capital increases [2][3] Summary by Sections Listing Details - The type of stock listing is categorized as "other," with a total of 434,236 shares available for subscription through offline methods [1] - The circulation date for the listed shares is set for December 22, 2025 [1] Share Capital Changes - Following the IPO on October 25, 2022, the company had 93,161,111 shares, with 73,115,709 shares under limited circulation and 20,045,402 shares freely tradable [1] - On December 22, 2022, the first exercise of the stock option plan resulted in the issuance of 361,862 shares, raising the total share count to 93,522,973 [2] - A subsequent capital increase on May 16, 2023, led to a further increase in total shares to 112,227,568 [2] - The second exercise of the stock option plan on March 11, 2024, added 266,148 shares, bringing the total to 112,493,716 [3] Lock-up Period and Commitments - The shares being listed are subject to a lock-up period of 36 months from the exercise date, which began on December 22, 2022 [2] - Shareholders involved in the stock option exercise have committed to not reducing their holdings during this period and will adhere to the same reduction regulations as the company's directors and senior management after the lock-up expires [3]